3834-86-4

Upstream product

• 1125-99-1 1-(1-Cyclohexen-1-yl)pyrrolidine 
• 628-77-3 1,5-diiodopentane 
• 108-94-1 cyclohexanone 
• 1119-51-3 bromopentene 

Downstream Products

• 67820-64-8 2--1-acetoxy-cyclohexen-(1) 
• 65727-66-4 2-methylbicyclo<4.4.0.>decan-1-ol 
• 65727-68-6 2-(4-Pentenyl)-cyclohexanol 
• 22627-53-8 1-Ethoxymethyl-2--cyclohexanol 
• 1111165-86-6 acetic acid 1-ethynyl-2-pent-4-enyl-cyclohexyl ester 
• 396080-19-6 C₁₁H₁₉NO 
• 22627-54-9 2--cyclohexan-carbaldehyd 
• 3643-57-0 2-(Penta-4-enyliden)-cyclohexan-1-on 
• 70298-95-2 (2-pent-4-enyl-cyclohexylidene)-methyl-amine oxide 

Relevant academic research and scientific papers

Oxidative cyclization reactions: Controlling the course of a radical cation-derived reaction with the use of a second nucleophile

Construction of new ring systems: Oxidative cyclizations (see picture; RVC=reticulated vitreous carbon) have been conducted that use two separate intramolecular nucleophiles to trap an enol ether-derived radical cation intermediate. The reactions provide

Gold- Vs. platinum-catalyzed polycyclizations by O-acyl migration. solvent-free reactions

Polycyclic derivatives incorporating a cyclopropyl group have been efficiently synthesized from propargyl acetates using platinum(II), gold(I) and gold(III) catalysis. These reactions which are also viable for the preparation of medium-sized rings, proceed with a complete diastereocontrol and can also be run in neat conditions.

COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS

A combination therapy comprising administration of a carbamoylating chemotherapeutic agent in conjunction with administration of a selective iNOS inhibitor compound is disclosed. Optionally, resection and radiation therapy are provided with the therapeutic combination. A medicament comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound together with a pharmaceutically acceptable carrier is further disclosed. A kit comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound is further disclosed.

METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS

Therapeutic methods for the prevention ad treatment of conditions and diseases of the gastrointestinal tract involving an overproduction of nitric oxide by inducible nitric oxide synthase are described, the methods including administering to a subject in need thereof a therapeutically effective amount of a selective inhibitor of inducible nitric oxide synthase (iNOS). The methods also include the use of selective inhibitors of iNOs in combination with other therapeutic agents, including antimicrobial agents and antisecretory agents.